|
|
|
| Research progress of NGF / TrKA signaling pathway in knee osteoarthritis pain#br# |
| LI Mingchao1 WANG Peimin2 YIN Songjiang2 ZHANG Li2 HUANG Zhengquan2 XING Runlin2 |
1.Department of Orthopaedics, the Third People’s Hospital of Kunshan, Jiangsu Province, Kunshan 215300, China;
2.Department of Orthopaedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, Nanjing 210029, China |
|
|
|
Abstract Pain is the main symptom of knee osteoarthritis (KOA), chronic pain seriously affects the quality of life of patients. KOA pain involves pathological changes such as inflammatory environment, cartilage damage, and nerve sensitization. Recent studies have shown that blocking nerve growth factor (NGF) successfully alleviates PAIN in KOA, confirming that NGF is a key mechanism of pain in knee osteoarthritis. This article reviews the research progress of NGF / Tropomyosin receptor kinase A signaling pathway and pathologic changes related to KOA pain.
|
|
|
|
|
|
[1] 何良志，路凡，滕飞，等.NGF/TrKA信号轴在骨关节炎中的研究进展[J].中国矫形外科杂志，2020，28（11）：933-936.
[2] Courties A，Sellam J. Osteoarthritis and type 2 diabetes mellitus：What are the links? [J]. Diabetes Res Clin Pract，2016，122：198-206. DOI：10.1016/j.diabres.2016.10.021.
[3] Fu K，Robbins SR，McDougall JJ. Osteoarthritis：the genesis of pain [J]. Rheumatology （Oxford），2018，57（suppl_4）：v43-v50. DOI：10.1093/rheumatology/kex419.
[4] Grassel S，Muschter D. Recent advances in the treatment of osteoarthritis [J]. F1000Res，2020：9. DOI：10.12688/f1000research.22115.1.
[5] Bowden JL，Hunter DJ，Deveza LA，et al. Core and adjunctive interventions for osteoarthritis：efficacy and models for implementation [J]. Nat Rev Rheumatol，2020，16（8）：434-447. DOI：10.1038/s41584-020-0447-8.
[6] Kloppenburg M，Berenbaum F. Osteoarthritis year in review 2019：epidemiology and therapy [J]. Osteoarthritis Cartilage，2020，28（3）：242-248. DOI：10.1016/j.joca.2020. 01.002.
[7] Norman BH，McDermott JS. Targeting the Nerve Growth Factor （NGF） Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain [J]. J Med Chem，2017，60（1）：66-88. DOI：10.1021/acs.jmedchem.6b00964.
[8] Capsoni S. From genes to pain：nerve growth factor and hereditary sensory and autonomic neuropathy type Ⅴ [J]. Eur J Neurosci，2014，39（3）：392-400. DOI：10.1111/ejn.12461.
[9] Khodorova A，Nicol GD，Strichartz G. The TrkA receptor mediates experimental thermal hyperalgesia produced by nerve growth factor：Modulation by the p75 neurotrophin receptor [J]. Neuroscience，2017，340：384-397. DOI：10. 1016/j.neuroscience.2016.10.064.
[10] Nencini S，Ringuet M，Kim DH，et al. Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain [J]. Mol Pain，2017，13：2071466509. DOI：10.1177/1744806917697011.
[11] Eitner A，Hofmann GO，Schaible HG. Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models [J]. Front Mol Neurosci，2017，10：349. DOI：10.3389/fnmol.2017.00349.
[12] Montagnoli C，Tiribuzi R，Crispoltoni L，et al. beta-NGF and beta-NGF receptor upregulation in blood and synovial fluid in osteoarthritis [J]. Biol Chem，2017，398（9）：1045-1054. DOI：10.1515/hsz-2016-0280.
[13] Neogi T，Guermazi A，Roemer F，et al. Association of Joint Inflammation With Pain Sensitization in Knee Osteoarthritis：The Multicenter Osteoarthritis Study [J]. Arthritis Rhe-umatol，2016，68（3）：654-661. DOI：10.1002/art.39488.
[14] Shang X，Wang Z，Tao H. Mechanism and therapeutic effectiveness of nerve growth factor in osteoarthritis pain [J]. Ther Clin Risk Manag，2017，13：951-956. DOI：10.2147/TCRM.S139814.
[15] Ayral X，Pickering EH，Woodworth TG，et al. Synovitis：a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients [J]. Osteoarthritis Cartilage，2005，13（5）：361-367. DOI：10.1016/j.joca.2005.01.005.
[16] Aso K，Shahtaheri SM，Hill R，et al. Contribution of nerves within osteochondral channels to osteoarthritis knee pain in humans and rats [J]. Osteoarthritis Cartilage，2020，28（9）：1245-1254. DOI：10.1016/j.joca.2020.05.010.
[17] Kc R，Li X，Kroin JS，et al. PKCdelta null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth [J]. Ann Rheum Dis，2016，75（12）：2133-2141. DOI：10.1136/annrheumdis-2015-208444.
[18] Jiang Y，Tuan RS. Role of NGF-TrkA signaling in calcification of articular chondrocytes [J]. FASEB J，2019，33（9）：10231-10239. DOI：10.1096/fj.201900970.
[19] Schnitzer TJ，Khan A，Bessette L，et al. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip：A 16-week dose-titration study [J]. Semin Arthritis Rheum，2020，50（3）：387-393. DOI：10.1016/j.semarthrit.2020.03. 004.
[20] Krupka E，Jiang GL，Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis：a randomized，double-blind and placebo-controlled study [J]. Osteoarthritis Cartilage，2019，27（11）：1599-1607. DOI：10.1016/j.joca.2019.05.028.
[21] 冼培凤，陈莹，杨路，等.蜂毒对胶原诱导性关节炎炎性痛大鼠背根神经节TrkA、TRPV1的影响[J].南方医科大学学报，2016，36（6）：838-841.
[22] Mayorga AJ，Flores CM，Trudeau JJ，et al. A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis [J]. Scand J Pain，2017，17：134-143. DOI：10. 1016/j.sjpain.2017.07.021.
[23] Sjogren E，Stahle L，Quiding H，et al. The effect of intradermal microdosing of a transient receptor potential cation channel subfamily V member 1 antagonist on heat evoked pain and thermal thresholds in normal and ultraviolet-C exposed skin in healthy volunteers [J]. Eur J Pain，2019，23（10）：1767-1779. DOI：10.1002/ejp.1451.
[24] Benitez-Del-Castillo JM，Moreno-Montanes J，Jimenez-Alfaro I，et al. Safety and Efficacy Clinical Trials for SYL1001，a Novel Short Interfering RNA for the Treatment of Dry Eye Disease [J]. Invest Ophthalmol Vis Sci，2016，57（14）：6447-6454. DOI：10.1167/iovs.16-20303.
[25] O’Neill TW，Felson DT. Mechanisms of Osteoarthritis （OA） Pain [J]. Curr Osteoporos Rep，2018，16（5）：611-616. DOI：10.1007/s11914-018-0477-1.
[26] 王度，张文明.膝关节骨性关节炎的分型进展及临床意义[J].中国矫形外科杂志，2020，28（1）：53-57.
[27] Hugle T，Geurts J. What drives osteoarthritis?-synovial versus subchondral bone pathology [J]. Rheumatol （Oxford），2017，56（9）：1461-1471. DOI：10.1093/rheumatology/kew389.
[28] Walsh DA. Editorial：Synovitis and Pain Sensitization [J]. Arthritis Rheumatol，2016，68（3）：561-562. DOI：10.1002/art.39487.
[29] Miller RE，Malfait AM，Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain [J]. Clin Exp Rheumatol，2017，35（5）：85-87.
[30] Chaumette T，Delay L，Barbier J，et al. c-Jun/p38MAPK/ASIC3 pathways specifically activated by nerve growth factor through TrkA are crucial for mechanical allodynia development [J]. Pain，2020，161（5）：1109-1123.
[31] 王迷娜，刘璐，赵洛鹏，等.膝骨关节炎炎性因子及信号通路的研究进展[J].中国骨伤，2020，33（4）：388-392.
[32] 张洪美.膝骨关节炎的规范诊治与阶梯治疗[J].中国骨伤，2019，32（5）：391-395. |
|
|
|
